Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

The new company, which was announced earlier this month, will bring together Syncona, the heath care investment company launched by the Wellcome Trust which has invested in a number of Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø spin-outs, BACIT - a listed investment fund set up to fund cancer research and the CRT Pioneer Fund, which was established by Cancer Research UK.

Syncona has been a leading investor in Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø spin-outs. Its recent investments include cancer immunotherapy companiesÌýÌýandÌýÌý, andÌý, which is developing gene therapies for bleeding and other disorders.

The new company will be listed on the London Stock Exchange and focus on cancer biotech investment.

Dr Celia Caulcott, Vice-Provost (Enterprise), said: "This is excellent news for biomedical research and particularly cancer treatment. The new fund will enable even more companies to be financed through the early development stage and we look forward to continuing our collaborative work with Syncona and the other partners in the venture."

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø has a long and successful track record of commercialising its research through its technology transfer companyÌýÏã¸ÛÁùºÏ²ÊÖÐÌØÍøB has launched over 60 spin-out companies to bring intellectual property developed by Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø researchers to market.

For more information on the new company, please click on the statement fromÌýand the article inÌý

Links